First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to ...

TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures, is ...

— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Profound ...

Detailed price information for Profound Medical Corp (PROF-Q) from The Globe and Mail including charting and trades.

Profound Medical (PROF) announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic ...

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...

Detailed price information for Profound Medical Corp (PROF-Q) from The Globe and Mail including charting and trades.

— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — “The various presentations made at AUA and other major ...

Q4-2025 revenue grew 43% year-over-year and 13% sequentially quarter-over-quarter to a record $6.0 million. Profound’s TULSA-PRO ® qualified sales pipeline also continues to grow, and currently stands ...